Contact
Please use this form to send email to PR contact of this press release:
Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01
TO:
Please use this form to send email to PR contact of this press release:
Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01
TO: